IVVD ▲ +1.5% - Invivyd, Inc.
$IVVD - Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
14-OCT-2026 07:01 AM ET
Share this post
More filings for $IVVD
IVVD ▲ +3.1% - Invivyd, Inc.Oct 21, 2026IVVD ▲ +3.2% - Invivyd, Inc.Sep 29, 2026IVVD ▲ +4.8% - Invivyd, Inc.Sep 8, 2026IVVD ▲ +6.2% - Invivyd, Inc.Sep 3, 2026IVVD ▼ -2.1% - Invivyd, Inc.Sep 1, 2026IVVD - Invivyd, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 15, 2026
View full $IVVD filing history →💬 Comments
Loading comments…
Leave a comment